Florfenicol

Florfenicol

SCHEMBL3030994

CS(=O)(=O)c1ccc([C@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 1.00
CYP3A4 P08684 3/20 1.00
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
TSHR P16473 2/20 0.78
RPLP1 P05386 1/20 0.51
RPLP0 P05388 1/20 0.51
RPS17 P08708 1/20 0.51
RPSA P08865 1/20 0.51
RPS2 P15880 1/20 0.51
RPL35A P18077 1/20 0.51
RPL7 P18124 1/20 0.51
RPL17 P18621 1/20 0.51
RPS4Y1 P22090 1/20 0.51
RPS3 P23396 1/20 0.51
RPS12 P25398 1/20 0.51
RPL13 P26373 1/20 0.51
RPL10 P27635 1/20 0.51
RPL12 P30050 1/20 0.51
RPL9; RPL9P7; RPL9P8; RPL9P9 P32969 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Florfenicol SCHEMBL49425 1.00 LMNA (1.00) LMNACYP3A4MEN1KMT2ATSHR
Florfenicol SCHEMBL651770 1.00 LMNA (1.00) LMNACYP3A4MEN1KMT2ATSHR
Florfenicol SCHEMBL3637832 1.00 LMNA (1.00) LMNACYP3A4MEN1KMT2ATSHR
Florfenicol SCHEMBL29833609 1.00 LMNA (1.00) LMNACYP3A4MEN1KMT2ATSHR
Florfenicol SCHEMBL4634861 0.99 LMNA (0.97) LMNACYP3A4MEN1KMT2ATSHR
Florfenicol SCHEMBL650814 0.97 LMNA (0.95) LMNACYP3A4MEN1KMT2ATSHR
Florfenicol SCHEMBL3817292 0.97 LMNA (0.95) LMNACYP3A4MEN1KMT2ATSHR
Florfenicol SCHEMBL648260 0.96 LMNA (0.93) LMNACYP3A4MEN1KMT2ATSHR
SCHEMBL12683654 0.96 LMNA (0.93) LMNACYP3A4MEN1KMT2ATSHR
Florfenicol SCHEMBL4421631 0.95 LMNA (0.90) LMNACYP3A4MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113710225-B Delivery and retention of active agents within the skin 范德生物公司 2024-06-21 CN disclosed
EP-3133061-B1 FLORFENICOL SYNTHESIZING METHOD MASTEAM BIO TECH CO LTD (CN) 2024-03-20 EP disclosed
US-20220175819-A1 DELIVERY AND RETENTION OF ACTIVE AGENTS WITHIN THE SKIN FOUNT BIO, INC. 2022-06-09 US disclosed
US-9951000-B2 Florfenicol synthesizing method MASTEAM BIO TECH CO LTD (CN) 2018-04-24 US disclosed
US-9951000-B2 Florfenicol synthesizing method MASTEAM BIO TECH CO LTD (CN) 2018-04-24 US disclosed
US-9951000-B2 Florfenicol synthesizing method MASTEAM BIO TECH CO LTD (CN) 2018-04-24 US disclosed
US-20170258930-A1 SKIN PENETRATING PEPTIDES (SPPS) AND METHODS OF USE THEREFOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-09-14 US disclosed
US-20170173173-A1 Skin Permeating and Cell Entering (SPACE) Peptides and Methods of Use Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-06-22 US disclosed
EP-3133061-A1 FLORFENICOL SYNTHESIZING METHOD Masteam Bio-tech Co. Ltd. (CN) 2017-02-22 EP disclosed
US-20160318859-A1 FLORFENICOL SYNTHESIZING METHOD MASTEAM BIO-TECH CO. LTD. 2016-11-03 US disclosed
US-20150025221-A1 Skin Permeating and Cell Entering (SPACE) Peptides and Methods of Use Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-01-22 US disclosed
US-20140227174-A1 SKIN PERMEATING AND CELL ENTERING (SPACE) PEPTIDES AND METHODS OF USE THEREFOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-08-14 US disclosed
US-8791062-B2 Skin permeating and cell entering (SPACE) peptides and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-07-29 US disclosed
US-20140161871-A1 SKIN PERMEATING AND CELL ENTERING (SPACE) PEPTIDES AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-06-12 US disclosed
US-8518871-B2 Skin permeating and cell entering (SPACE) peptides and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-08-27 US disclosed
US-20120128756-A1 Skin Permeating And Cell Entering (SPACE) Peptides and Methods of Use Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-05-24 US disclosed
US-8084643-B2 Nitrogen-containing esters of the secondary alcohol group of florfenicol and of its analogs,including salts; veterinary medicine; nonhydrolyzing as needed to maintain the prodrug in aqueous solution in the subjects system until appropriate; cattle drinking water; bovine respiratory disease INTERVET INC. (US) 2011-12-27 US disclosed
US-20100210851-A1 PROCESS FOR PREPARING OXAZOLIDINE- AND OXAZOLIDINONE-AMINODIOLS INTERVET, INC. 2010-08-19 US disclosed
US-20090170954-A1 Process for Recovering Florfenicol and Florfenicol Analogs SCHERING-PLOUGH LTD. (CH) 2009-07-02 US disclosed
US-20080188556-A1 Water-Soluble Prodrugs of Florfenicol and its Analogs SCHERING-PLOUGH ANIMAL HEALTH CORPORATION 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175819-A1 DELIVERY AND RETENTION OF ACTIVE AGENTS WITHIN THE SKIN MMP8, MMP7, MMP1 LMNA 928/4885CYP3A4 4437/4885MEN1 4375/4885
US-20080188556-A1 Water-Soluble Prodrugs of Florfenicol and its Analogs PFAS, ADH5, SI LMNA 2524/4885CYP3A4 15/4885MEN1 2179/4885
US-20160318859-A1 FLORFENICOL SYNTHESIZING METHOD CYP2C19, DDC, CYP3A4 LMNA 3913/4885CYP3A4 3/4885MEN1 3747/4885
US-20100210851-A1 PROCESS FOR PREPARING OXAZOLIDINE- AND OXAZOLIDINONE-AMINODIOLS OXA1L, AZI2, CYP4F2 LMNA 1521/4885CYP3A4 22/4885MEN1 1598/4885
US-20090170954-A1 Process for Recovering Florfenicol and Florfenicol Analogs FDPS, FAU, PFAS LMNA 3693/4885CYP3A4 11/4885MEN1 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.